Preferentially expressed antigen in melanoma (PRAME) immunohistochemistry is currently used in pathology for the assessment of melanocytic neoplasms; however, knowledge of its expression patterns in soft tissue tumors is limited. PRAME immunohistochemistry (clone QR005) was assessed on whole tissue sections of 350 soft-tissue tumors and mimics (> 50 histotypes). PRAME immunoreactivity was evaluated as follows: 0 "negative" (0% positive cells); 1+ (1-25% positive cells); 2+ (26-50% positive cells); 3+ (51-75% positive cells), and 4+ "diffuse" (> 75% positive cells). PRAME was expressed in 111 lesions (0 benign, 6 intermediate malignancy, and 105 malignant), including fibrosarcomatous dermatofibrosarcoma protuberans (2/4, 0 diffuse), NTRK-rearranged spindle cell neoplasm (2/4, 0 diffuse), atypical fibroxanthoma (1/7, 0 diffuse), Kaposi sarcoma (1/5, 0 diffuse), myxoid liposarcoma (11/11, 9 diffuse), synovial sarcoma (11/11, 6 diffuse), intimal sarcoma (7/7, 5 diffuse), biphenotypic sinonasal sarcoma (3/3, 1 diffuse), angiosarcoma (10/15, 6 diffuse), malignant peripheral nerve sheath tumor (9/12, 4 diffuse), pleomorphic rhabdomyosarcoma (2/3, 2 diffuse), alveolar rhabdomyosarcoma (2/6, 0 diffuse), embryonal rhabdomyosarcoma (7/7, 4 diffuse), undifferentiated pleomorphic sarcoma (2/12, 1 diffuse), leiomyosarcoma (2/15, 1 diffuse), clear cell sarcoma of soft tissue (1/10, 0 diffuse), low-grade fibromyxoid sarcoma (1/5, 0 diffuse), Ewing sarcoma (2/10, 1 diffuse), CIC-rearranged sarcoma (8/8, 4 diffuse), BCOR-sarcoma (2/5, 1 diffuse), melanoma (20/20, 14 diffuse), and thoracic SMARCA4-deficient undifferentiated tumor (5/5, all diffuse). All tested cases of spindle cell lipoma, dedifferentiated/pleomorphic liposarcoma, dermatofibrosarcoma protuberans, solitary fibrous tumor, inflammatory myofibroblastic tumor, myxoinflammatory fibroblastic sarcoma, nodular fasciitis, myxofibrosarcoma, epithelioid hemangioendothelioma, atypical vascular lesion, hemangioma, lymphangioma, vascular malformation, papillary endothelial hyperplasia, GIST, gastrointestinal clear-cell sarcoma, malignant melanotic nerve sheath tumor, neurofibroma, schwannoma, granular cell tumor, alveolar soft part sarcoma, epithelioid sarcoma, extraskeletal myxoid chondrosarcoma, myoepithelioma, ossifying fibromyxoid tumor, angiomatoid fibrous histiocytoma, PEComa, dermatofibroma, pleomorphic dermal sarcoma, and chordoma were negative. PRAME shows imperfect specificity in soft-tissue pathology but may serve as a diagnostic adjunct in selected differential diagnoses that show contrasting expression patterns.

Bioptical Laboratory Ltd Plzen Czech Republic

Department of Biopathology Institut Bergonié Bordeaux France

Department of Pathology Bordeaux University Hospital UMR 1312 Inserm Bordeaux France

Department of Pathology Faculty of Medicine in Plzen Charles University Pilsen Czech Republic

INSERM U1218 ACTION Institut Bergonié Bordeaux France

University of Bordeaux Talence France

Zobrazit více v PubMed

Ikeda H, Lethé B, Lehmann F et al (1997) Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6:199–208. https://doi.org/10.1016/s1074-7613(00)80426-4 PubMed DOI

Epping MT, Wang L, Edel MJ, Carlée L, Hernandez M, Bernards R (2005) The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell 122:835–847. https://doi.org/10.1016/j.cell.2005.07.003 PubMed DOI

Oehler VG, Guthrie KA, Cummings CL et al (2009) The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells. Blood 114:3299–3308. https://doi.org/10.1182/blood-2008-07-170282 PubMed DOI PMC

Gutzmer R, Rivoltini L, Levchenko E et al (2016) Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study. ESMO Open 1:e000068. https://doi.org/10.1136/esmoopen-2016-000068 PubMed DOI PMC

Pujol JL, De Pas T, Rittmeyer A et al (2016) Safety and immunogenicity of the PRAME cancer immunotherapeutic in patients with resected non-small cell lung cancer: a phase I dose escalation study. J Thorac Oncol 11:2208–2217. https://doi.org/10.1016/j.jtho.2016.08.1206 PubMed DOI

Gezgin G, Luk SJ, Cao J et al (2017) PRAME as a potential target for immunotherapy in metastatic uveal melanoma. JAMA Ophthalmol 135:541–549. https://doi.org/10.1001/jamaophthalmol.2017.0729 PubMed DOI PMC

Gradecki SE, Valdes-Rodriguez R, Wick MR, Gru AA (2021) PRAME immunohistochemistry as an adjunct for diagnosis and histological margin assessment in lentigo maligna. Histopathology 78:1000–1008. https://doi.org/10.1111/his.14312 PubMed DOI

Alomari AK, Tharp AW, Umphress B, Kowal RP (2021) The utility of PRAME immunohistochemistry in the evaluation of challenging melanocytic tumors. J Cutan Pathol 48:1115–1123. https://doi.org/10.1111/cup.14000 PubMed DOI

Lezcano C, Pulitzer M, Moy AP, Hollmann TJ, Jungbluth AA, Busam KJ (2020) Immunohistochemistry for PRAME in the distinction of nodal nevi from metastatic melanoma. Am J Surg Pathol 44:503–508. https://doi.org/10.1097/pas.0000000000001393 PubMed DOI PMC

Lezcano C, Jungbluth AA, Busam KJ (2021) PRAME immunohistochemistry as an ancillary test for the assessment of melanocytic lesions. Surg Pathol Clin 14:165–175. https://doi.org/10.1016/j.path.2021.01.001 PubMed DOI PMC

Gradecki SE, Slingluff CL, Gru AA (2021) PRAME expression in 155 cases of metastatic melanoma. J Cutan Pathol 48:479–485. https://doi.org/10.1111/cup.13876 PubMed DOI

Santandrea G, Valli R, Zanetti E et al (2022) Comparative analysis of PRAME expression in 127 acral and nail melanocytic lesions. Am J Surg Pathol 46:579–590. https://doi.org/10.1097/pas.0000000000001878 PubMed DOI

Kaczorowski M, Chłopek M, Kruczak A, Ryś J, Lasota J, Miettinen M (2022) PRAME expression in cancer. a systematic immunohistochemical study of >5800 epithelial and nonepithelial tumors. Am J Surg Pathol 46:1467–1476. https://doi.org/10.1097/pas.0000000000001944 PubMed DOI

Raghavan SS, Wang JY, Toland A et al (2020) Diffuse PRAME expression is highly specific for malignant melanoma in the distinction from clear cell sarcoma. J Cutan Pathol 47:1226–1228. https://doi.org/10.1111/cup.13812 PubMed DOI

Chen YP, Zhang WW, Qiu YT, Ke LF, Chen H, Chen G (2023) PRAME is a useful marker for the differential diagnosis of melanocytic tumours and histological mimics. Histopathology 82:285–295. https://doi.org/10.1111/his.14814 PubMed DOI

Googe PB, Flanigan KL, Miedema JR (2021) Preferentially expressed antigen in melanoma immunostaining in a series of melanocytic neoplasms. Am J Dermatopathol 43:794–800. https://doi.org/10.1097/dad.0000000000001885 PubMed DOI

Ferrara G, Argenziano G (2021) The WHO 2018 classification of cutaneous melanocytic neoplasms: suggestions from routine practice. Front Oncol 11:675296. https://doi.org/10.3389/fonc.2021.675296 PubMed DOI PMC

Gassenmaier M, Hahn M, Metzler G et al (2021) Diffuse PRAME expression is highly specific for thin melanomas in the distinction from severely dysplastic nevi but does not distinguish metastasizing from non-metastasizing thin melanomas. Cancers 13:3864. https://doi.org/10.3390/cancers13153864 PubMed DOI PMC

Gerami P, Benton S, Zhao J et al (2022) PRAME expression correlates with genomic aberration and malignant diagnosis of spitzoid melanocytic neoplasms. Am J Dermatopathol 44:575–580. https://doi.org/10.1097/dad.0000000000002208 PubMed DOI

Agaimy A, Stoehr R, Hornung A et al (2021) Dedifferentiated and undifferentiated melanomas: report of 35 new cases with literature review and proposal of diagnostic criteria. Am J Surg Pathol 45:240–254. https://doi.org/10.1097/PAS.0000000000001645 PubMed DOI

Cadwell CR, Yuksek GE, Hirbe AC et al (2021) Preferentially expressed antigen in melanoma (PRAME) expression in malignant, but not benign, peripheral nerve sheath tumors. J Neuropathol Exp Neurol 80:384–386. https://doi.org/10.1093/jnen/nlaa125 PubMed DOI

Cesinaro AM, Piana S, Paganelli A, Pedroni G, Santandrea G, Maiorana A (2022) PRAME expression in cellular neurothekeoma: a study of 11 cases. J Cutan Pathol 49:338–342. https://doi.org/10.1111/cup.14163 PubMed DOI

WHO Classification of Tumours editorial board (2020) Soft tissue and bone tumours 5th edn. International Agency for Research on Cancer, Lyon, France

Albertsmeier M, Altendorf-Hofmann A, Lindner LH et al (2020) Cancer testis antigens and immunotherapy: expression of PRAME is associated with prognosis in soft tissue sarcoma. Cancers 12:3612. https://doi.org/10.3390/cancers12123612 PubMed DOI PMC

Hrycaj SM, Szczepanski J, Zhao L et al (2022) PRAME expression in spindle cell melanoma, malignant peripheral nerve sheath tumor, and other cutaneous sarcomatoid neoplasms: a comparative analysis. Histopathology 81:818–825. https://doi.org/10.1111/his.14797 PubMed DOI PMC

Iura K, Maekawa A, Kohashi K et al (2017) Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1. Hum Pathol 61:130–139. https://doi.org/10.1016/j.humpath.2016.12.006 PubMed DOI

Lezcano C, Müller AM, Frosina D et al (2021) Immunohistochemical detection of cancer-testis antigen PRAME. Int J Surg Pathol 29:826–835. https://doi.org/10.1177/10668969211012085 PubMed DOI

Wang L, Zehir A, Sadowska J et al (2015) Consistent copy number changes and recurrent PRKAR1A mutations distinguish melanotic schwannomas from melanomas: SNP-array and next generation sequencing analysis. Genes Chromosom Cancer 54:463–471. https://doi.org/10.1002/gcc.22254 PubMed DOI

Guo T, Zhang L, Chang NE, Singer S, Maki RG, Antonescu CR (2011) Consistent MYC and FLT4 gene amplification in radiation-induced angiosarcoma but not in other radiation-associated atypical vascular lesions. Genes Chromosom Cancer 50:25–33. https://doi.org/10.1002/gcc.20827 PubMed DOI

Iura K, Kohashi K, Hotokebuchi Y et al (2015) Cancer-testis antigens PRAME and NY-ESO-1 correlate with tumour grade and poor prognosis in myxoid liposarcoma. J Pathol Clin Res 1:144–159. https://doi.org/10.1002/cjp2.16 PubMed DOI PMC